Effectiveness and Limitation of Gamma Knife Radiosurgery for Relapsed Central Nervous System Lymphoma: A Retrospective Analysis in One Institution

2007 ◽  
Vol 85 (4) ◽  
pp. 333-337 ◽  
Author(s):  
Yosuke Matsumoto ◽  
Shigeo Horiike ◽  
Yoshiko Fujimoto ◽  
Daisuke Shimizu ◽  
Yuriko Kudo-Nakata ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Retrospective Analysis ◽  
Gamma Knife ◽  
Gamma Knife Radiosurgery ◽  
Central Nervous System Lymphoma

Gamma Knife Radiosurgery in AIDS-Related Primary Central Nervous System Lymphoma

1995 ◽  
Vol 64 (1) ◽  
pp. 42-55 ◽  
Author(s):  
A. Nicolato ◽  
M.A. Gerosa ◽  
R. Foroni ◽  
E. Piovan ◽  
P.G. Zampieri ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Gamma Knife ◽  
Gamma Knife Radiosurgery ◽  
Central Nervous System Lymphoma

scholarly journals RT-23 * THE ROLE OF GAMMA KNIFE RADIOSURGERY IN THE TREATMENT FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS

2014 ◽  
Vol 16 (suppl 5) ◽  
pp. v192-v192
Author(s):  
K. Mori ◽  
Y. Chiba ◽  
S. Toyota ◽  
T. Kumagai ◽  
S. Yamamoto ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Gamma Knife ◽  
Gamma Knife Radiosurgery

scholarly journals Management of Primary Central Nervous System Lymphoma Using Intra-Arterial Chemotherapy With Osmotic Blood-Brain Barrier Disruption: Retrospective Analysis of the Sherbrooke Cohort

2021 ◽  
Vol 10 ◽  
Author(s):  
Christian Iorio-Morin ◽  
Gérald Gahide ◽  
Christophe Morin ◽  
Davy Vanderweyen ◽  
Marie-André Roy ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Retrospective Analysis ◽  
Blood Brain Barrier ◽  
Central Nervous System Lymphoma ◽  
Brain Barrier ◽  
Rank Test ◽  
High Dose ◽  
Hematologic Toxicity ◽  
Blood Brain

BackgroundPrimary central nervous system lymphomas (PCNSL) are rare and aggressive CNS tumors. Current management involves high-dose methotrexate (HD-MTX) typically administered intravenously (IV), despite the existence of the blood-brain barrier (BBB), which significantly decreases its bioavailability. Cerebral intra-arterial chemotherapy (CIAC) coupled with osmotic BBB disruption (OBBBD) can theoretically circumvent this issue.MethodsWe performed a retrospective analysis of patients with newly diagnosed PCNSL treated with HD-MTX-based CIAC+OBBBD at our center between November 1999 and May 2018. OBBBD was achieved using a 25% mannitol intra-arterial infusion. Patients were followed clinically and radiologically every month until death or remission. Demographics, clinical and outcome data were collected from the medical record. All imaging studies were reviewed for evidence of complication and outcome assessment. Kaplan-Meier analyses were used to compute remission, progression-free survival (PFS) as well as overall survival times. Subgroup analyses were performed using the log rank test.ResultsForty-four patients were included in the cohort. Median follow-up was 38 months. Complete response was achieved in 34 patients (79%) at a median of 7.3 months. Actuarial median survival and PFS were 45 months and 24 months, respectively. Age, ECOG and lesion location did not impact outcome. Complications included thrombocytopenia (39%), neutropenia (20%), anemia (5%), seizures (11%), stroke (2%), and others (20%).ConclusionCIAC using HD-MTX-based protocols with OBBBD is a safe and well-tolerated procedure for the management of PCNSL. Our data suggests better PFS and survival outcomes compared to IV protocols with less hematologic toxicity and good tolerability, especially in the elderly.

Gamma Knife surgery for primary central nervous system lymphoma: usefulness as palliative local tumor control

2006 ◽  
Vol 105 (Supplement) ◽  
pp. 133-138 ◽  
Author(s):  
Hiroyuki Kenai ◽  
Masanori Yamashita ◽  
Takaharu Nakamura ◽  
Tomoshige Asano ◽  
Yasutomo Momii ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Central Nervous System ◽  
Nervous System ◽  
Gamma Knife ◽  
Central Nervous System Lymphoma ◽  
Local Tumor Control ◽  
Gamma Knife Surgery ◽  
Tumor Control ◽  
Local Tumor

ObjectAlthough there is no established treatment for primary central nervous system lymphoma (PCNSL), therapeutic protocols involving high-dose methotrexate therapy followed, in some cases, by whole-brain radiotherapy (WBRT) have generally been adopted, and they have yielded relatively favorable results. Gamma Knife surgery (GKS) is a stopgap measure to treat patients with PCNSL. The authors summarize the results of their cases and evaluate the efficacy and usefulness of GKS.MethodsBetween June 1999, and June 2005, 22 patients suffering from PCNSL were treated with GKS at the authors' institution and were followed up for more than 6 months. Some combination of chemotherapy and/or WBRT and/or microsurgery had been performed in 18 of the 22 patients before GKS. The remaining four patients had not undergone any previous treatment. In these patients, the mean tumor volume was 4.14 cm3, and the tumors were treated with a mean margin dose of 16.5 Gy to the 52.8% isodose line. Magnetic resonance imaging demonstrated the disappearance of the GKS-treated lesions; however, new lesions were observed in other regions of the brain in 10 patients and repeated GKS was performed in some cases. No local recurrences were observed an average of 19.4 months after GKS, and good level of quality of life (QOL) was maintained during this period.Conclusions Gamma Knife surgery should be performed only for local tumor control as a stopgap measure in the treatment of PCNSL. It is noninvasive and safe, and its effects occur rapidly. Its use improves prognosis and enhances the patient's quality of life. Gamma Knife surgery should be considered one of the treatment strategies for patients with PCNSLs.

Sign in / Sign up

Export Citation Format

Share Document